Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
IRLAB Therapeutics AB Class A ( ($SE:IRLAB.A) ) has shared an announcement.
IRLAB Therapeutics AB has successfully registered a rights issue, converting paid subscribed shares into regular shares, raising approximately SEK 115.7 million before costs. This financial move is expected to bolster the company’s operations, potentially enhancing its market position and offering reassurance to stakeholders about its ongoing development projects.
More about IRLAB Therapeutics AB Class A
IRLAB Therapeutics AB is a Swedish company focused on discovering and developing transformative treatments for all stages of Parkinson’s disease. Originating from Nobel Laureate Prof Arvid Carlsson’s research, the company is advancing several compounds, including Mesdopetam for levodopa-induced dyskinesias and Pirepemat for reducing fall frequency in Parkinson’s patients. Their research platform, Integrative Screening Process (ISP), supports their pipeline development.
Average Trading Volume: 106,396
Technical Sentiment Signal: Sell
Current Market Cap: SEK265.6M
For detailed information about IRLAB.A stock, go to TipRanks’ Stock Analysis page.
Trending Articles:
- “The No. 1 Destination for the Most Talented Artists”: Netflix Stock (NASDAQ:NFLX) Notches Up as the Duffer Brothers Consider Jumping Ship
- “Breakthrough EVs”: Ford Stock (NYSE:F) Notches Up on New Battery Details
- “An Equity Stake”: Intel Stock (NASDAQ:INTC) Surges as U.S. Government May Buy In With CHIPS Act Money